10:53 AM EST, 02/18/2025 (MT Newswires) -- Chimerix ( CMRX ) said Tuesday the US Food and Drug Administration has accepted a new drug application seeking accelerated approval for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma.

The application has been granted priority review and assigned a target action date of Aug. 18, the company said, adding the FDA does not plan to hold an advisory committee meeting to discuss the application.

Chimerix ( CMRX ) shares were rising past 15% in recent trading.

Price: 5.01, Change: +0.63, Percent Change: +14.38